TB500 (FRAG)

Research Use Only. Not for Human Consumption.

TB500 (FRAG) is supplied by Nexus as a 10mg lyophilized research material categorized under Healing & Recovery. The supplied chemistry record identifies this SKU as a thymosin beta-4 active fragment rather than a full-length TB-500 / thymosin beta-4 product. Because fragment and full-length thymosin labels are frequently conflated in vendor catalogs, this page treats the compound narrowly: TB-500 fragment 17-23, commonly represented as N-acetylated LKKTETQ.

The available source data for this SKU is chemistry-focused and does not include batch-level purity, retention time, mass-found values, supplier COA attributes, or peer-reviewed citation metadata. Nexus therefore does not add unsupported claims, therapeutic interpretations, dosage guidance, or extrapolated literature summaries for this product page.

Compound Overview

TB500 (FRAG) is described in the provided research record as a short thymosin beta-4 active fragment. The structural description is TB-500 fragment 17-23, commonly represented as N-acetylated LKKTETQ. The amino-acid sequence supplied for the fragment is LKKTETQ, with the display representation Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln.

This distinction matters for catalog accuracy. A short 7-residue active fragment is chemically distinct from full-length thymosin beta-4 / TB-500 style products. The source record specifically flags that vendor labeling can conflate full-length TB-4 or TB-500 material with the 7-residue fragment. For this reason, Nexus labels this product as TB500 (FRAG) and presents the compound by its fragment classification, sequence representation, molecular formula, and computed molecular weight rather than implying equivalence with a full-length peptide.

The listed research size is 10mg, associated with SKU B10F. Intended use is restricted to in-vitro research workflows only. This material is not supplied for human consumption, veterinary use, therapeutic use, diagnostic use, disease prevention, or any bodily application.

Research Background & Published Literature

The research data available for TB500 (FRAG) supports a limited, chemistry-centered background. It identifies the product as a thymosin beta-4 active fragment and notes that the relevant fragment is commonly represented as N-acetylated LKKTETQ. No peer-reviewed citation list was supplied with this SKU, and the available record does not provide study abstracts, experimental models, assay conditions, or literature-derived mechanism claims.

Because the source data is intentionally narrow, Nexus does not extend this section with inferred biological outcomes or human-use conclusions. The product page should be read as a technical identity profile for an in-vitro research reagent: classification, fragment sequence, molecular formula, molecular weight, physical form, storage guidance, and documentation expectations.

The provided public reference sources for fragment-level chemical context are listed below. They are included only as source references supplied with the research record, not as expanded clinical, therapeutic, or dosing support:

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Bock-Marquette et al. (2004) — Nature
• Wyczółkowska et al. (2007) — Peptides

Storage, Handling & Stability Guidelines

Store lyophilized TB500 (FRAG) at -20°C, desiccated and protected from light. The supplied storage guidance emphasizes moisture control, light protection, and reduced freeze-thaw exposure as core handling priorities for the lyophilized material and any reconstituted aliquots prepared under laboratory procedures.

• Keep lyophilized material sealed, desiccated, protected from light, and stored at -20°C.
• After reconstitution, aliquot according to the laboratory's validated workflow.
• Avoid repeated freeze-thaw cycles after reconstitution.
• Use appropriate laboratory PPE and handling controls for research reagents.
• Label aliquots clearly with compound name, sequence or fragment identifier where applicable, preparation date, and operator initials.

The source data does not specify a reconstitution solvent, concentration, post-reconstitution expiration interval, or validated stability study. Nexus therefore does not provide solvent selection, dosage, or timing guidance for this SKU.

Lab Verification

Nexus references batch-level documentation through the Lab Verified workflow when current lot records are available. For peptide research materials, lab verification may include High-Performance Liquid Chromatography (HPLC) for chromatographic purity review and Mass Spectrometry (MS) for identity or mass confirmation.

No exact COA attributes were provided in the TB500 (FRAG) source record. This page does not list a batch number, purity percentage, retention time, mass-found value, analyst name, test date, or COA-derived release result. Because the source record also flags the need to confirm whether supplier documentation corresponds to Ac-LKKTETQ fragment rather than full-length thymosin beta-4, researchers should review the applicable lot documentation in the Lab Verified archive when it is available.